Harmony Biosciences Holdings, Inc. - 8-K Filing

Harmony Biosciences reports Q3 2026 WAKIX net revenue of $268.9 million and announces CEO succession plan. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $HRMY

Read the full article at SEC EDGAR

More Regulatory news